AGI discontinues Rezular

AGI Therapeutics plc (ISE:A9I; LSE:AGI) closed down 23.5p (59%) to 16p on LSE and down EUR 0.32 (68%) to EUR 0.15 on ISE on Friday after discontinuing development of Rezular arverapamil for diarrhea-predominant irritable bowel syndrome (IBS-D). The move came after top-line data from the Phase III ARDIS-1 trial showed that Rezular missed the primary endpoint of patient reported adequate relief of IBS symptoms. The double-blind, placebo-controlled, international trial enrolled 711 subjects. Rezular is an oral formulation of the R-isomer of verapamil. ...